Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Haematological malignancies

208MO - Immune related adverse events and biomarkers after Anbal-cel, novel anti-CD19 CAR-T therapy with dual silencing of PD-1 and TIGIT: Updates from phase I study


04 Dec 2022


Mini Oral session: Haematological malignancies


Clinical Research;  Cell-Based Therapy;  Immunotherapy

Tumour Site



Won Seog Kim


Annals of Oncology (2022) 33 (suppl_9): S1515-S1520. 10.1016/annonc/annonc1127


W.S. Kim1, S.J. Kim2, S.E. Yoon2, J. Kim3

Author affiliations

  • 1 Division Of Hematology And Oncology, Department Of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 06351 - Seoul/KR
  • 2 Hematology - Oncology Dept., Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 3 Clinical Development, Curocell Inc., 34109 - Daejeon/KR


Login to access the resources on OncologyPRO.

Abstract 208MO


Anbal-cel is a novel 2nd generation autologous CD19 CAR-T cell therapy which has been knock-downed for PD-1 and TIGIT using OVIS platform and demonstrated the superior T-cell functionality compared with CD19 CAR-T cells at preclinical studies.


This Phase 1 dose escalation part was evaluated for the safety and preliminary efficacy in patients with r/r LBCL. Anbal-cel was administered at dose level 1 (2x105 cells/kg), DL2 (7x105 cells/kg) or DL3 (2x106 cells/kg). Blood samples have been collected to assess PK, cytokine levels, immune phenotypes and safety etc.


As of May 25 2022, 11 patients with r/r DLBCL were infused with Anbal-cel; 4pts at DL1, 3pts at DL2 and 4pts at DL3. Median manufacturing time was 8 days (range 5-11) and median CD4:CD8 ratio of final product was 1.1. Median knock-down rate of PD-1 and TIGIT was 65% and 96% respectively. Complete response rate was 82% (9/11) and CAR genes were detectable at 6 months in 4 out 5 evaluable patients by qPCR method. Of 11 patients, 5 (45%) experienced CRS with median onset time of 7 days (range 1-16) and median duration of 5 days (range 1-19) and 2 (18%) experienced grade 3 CRS. One patient dosed at DL3 experienced grade 2 ICANS. Grade ≥3 Anemia, neutropenia and thrombocytopenia at day 28 was observed at 22%, 82%, 55% respectively and incidence of grade ≥3 cytopenia was correlated with the dose of Anbal-cel. The Peak levels of IL-2, 6, 8, 10, TNF-α and MCP-1 were increased proportionally to the dose of Anbal-cel while the peak of IFN-γ ramined indifferent depending on the dose of Anbal-cel. B-cell aplasia was maintained from all responding patients by flow cytometry except for one patient at DL2 whose B-cell was reappeared at 3 months and documented PD at 5 months after achieving CR. LDH and CRP changes were inversely proportional to the dose of Anbal-cel but Ferritin level wasn't found to be related to the dose of Anbal-cel.


Anbal-cel expanded proportionally to the infused dose and cytokines were increased in response to the level of Anbal-cel expanded. Concurrent with the increased Anbal-cel expansion and cytokine levels, prolonged cytopenia was observed in dose responsive manner and these are planned to be further investigated in phase 2.

Clinical trial identification

CRC01-01 (NCT04836507).

Editorial acknowledgement

Legal entity responsible for the study

Curocell Inc.


Curocell Inc.


J. Kim: Financial Interests, Institutional, Full or part-time Employment: Curocell. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.